Oncology

We are leading a revolution in oncology to redefine cancer care

Explore our key disease areas

View latest Oncology news

We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.

Our Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. Our broad pipeline of next-generation medicines, together with our focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.

We focus on four strategic priorities:

Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies

Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients

Building expertise and leadership in the most prevalent and highest mortality rate tumour types

Delivering across our global footprint

Our clinical strategy aims to transform survival.

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care.

We are catalysing changes in the practice of medicine to transform the patient experience.

Our people, passion and innovation drive us.

Our focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.

Lung cancer

We are at the forefront of lung cancer treatment. Learn how we are prioritising precision medicine to deliver medicines matched to the patients who can best benefit from them in early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.

Breast cancer

We have a long history in breast cancer and have always followed the science in providing innovative treatments. The way in which breast cancer is classified is evolving, learn more about how we are redefining how we treat breast cancer in the future.

Ovarian cancer

We are augmenting our commitment to ovarian cancer. Read more on our approach to using ground-breaking science to further our understanding of the many biomarkers involved in ovarian cancer and how new therapies can be used to target these and improve outcomes.

Blood cancer

We are pushing the boundaries of science to redefine care in haematology. Read more about our approach to tackling blood cancers, a diverse and complex family of diseases, and our commitment to delivering a meaningful impact on care, shaped by patient insights.

Prostate cancer

We have a personalised approach to prostate cancer. Learn more about the role that genetics and biomarkers can play in this disease and how our personalised approach is combatting these features of prostate cancer.

Liver cancer

We are exploring novel immunotherapy combinations for overcoming the drivers of immunosuppression involved in liver cancer. Read more about our ambition to improve survival for these patients who are in urgent need of new effective treatments.

Pancreatic cancer

We are leading the revolution in pancreatic cancer. Learn more about this hard to detect cancer and how our ongoing research into the biomarkers involved has given rise to improved understanding and targeted therapies.

Cervical cancer

We are targeting cervical cancer with cure in mind. Learn more about how we are working to help turn the tide against cervical cancer by providing the immune system with tools to recognise and respond to the presence of tumour cells that our innate immune surveillance mechanisms may have missed.

In 2020, we partnered with global patient coalitions around the world to launch New Normal, Same Cancer. This programme raises awareness of the impact of the COVID-19 pandemic on cancer care and calls for those experiencing new symptoms or are waiting to attend routine screening appointments not to wait any longer to contact their doctor.

Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance. Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care.

We have partnered with leading solution providers, scientific societies and clinical experts to create HAYA (pronounced hah-yah) - a fully-integrated cancer care management platform for patients, healthcare providers and care centres. HAYA addresses the need for simplification of the oncology patient pathway by enabling continuity of care and connectivity between healthcare professionals and patients. This unique platform combines telemonitoring, teleconsultation, home care services, treatment navigation, personalised support, tracking, motivation and education – all through a single interface. HAYA provides a holistic and personalised view of care plans from diagnosis to treatment to follow up.

Dave Fredrickson

Executive Vice-President, Oncology Business Unit

View Dave’s profile

Susan Galbraith

Executive Vice-President, Oncology R&D

View Susan’s profile

Ti Hwei How

Vice-President, International Oncology

View Ti Hwei's profile

Be among colleagues who are driven by our passion, our people and a culture of innovation. We value courage, curiosity, collaboration, and a passion for learning. We encourage disruptive thinking where failure is an opportunity to learn – having the freedom to take risks without fear of failure.

AstraZeneca Careers

Our resources

Sharing clinical trials information

We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.

Visit website

Information about our medicines

Our medicines are approved in individual countries for specific uses. Visit your local AstraZeneca site to find out more.

Select country

Latest news

17 January 2022

Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

Corporate Press Release

13 January 2022

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU

Corporate Press Release

13 January 2022

AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets

Corporate Press Release

12 December 2021

Calquence reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial

Corporate Press Release

9 December 2021

Enhertu additional analyses further reinforce ground-breaking efficacy in patients with HER2-positive metastatic breast cancer

Corporate Press Release

3 December 2021

AstraZeneca reinforces leadership in breast cancer at SABCS 2021 with new data underscoring ambition to redefine cancer care

Corporate Press Release

View all news and press releases

Veeva ID: Z4-40328
Date of preparation: November 2021